Equities research analysts forecast that Galena Biopharma, Inc. (NASDAQ:GALE) will announce earnings per share (EPS) of ($0.15) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Galena Biopharma’s earnings. Galena Biopharma posted earnings of ($0.58) per share in the same quarter last year, which would suggest a positive year over year growth rate of 74.1%. The firm is expected to report its next earnings report on Wednesday, March 21st.

According to Zacks, analysts expect that Galena Biopharma will report full-year earnings of ($0.59) per share for the current year. For the next financial year, analysts forecast that the firm will report earnings of ($0.84) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Galena Biopharma.

Large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC purchased a new stake in shares of Galena Biopharma in the 1st quarter valued at about $976,000. Vanguard Group Inc. lifted its holdings in shares of Galena Biopharma by 1.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,332,434 shares of the biotechnology company’s stock valued at $774,000 after purchasing an additional 13,302 shares during the last quarter. Virtu KCG Holdings LLC lifted its holdings in shares of Galena Biopharma by 677.4% in the 2nd quarter. Virtu KCG Holdings LLC now owns 224,050 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 195,230 shares during the last quarter. Finally, Vaughan David Investments Inc. IL lifted its holdings in shares of Galena Biopharma by 6,545.7% in the 3rd quarter. Vaughan David Investments Inc. IL now owns 864,076 shares of the biotechnology company’s stock valued at $20,893,000 after purchasing an additional 851,074 shares during the last quarter. 19.00% of the stock is owned by institutional investors and hedge funds.

Galena Biopharma (NASDAQ:GALE) remained flat at $$0.28 during trading hours on Thursday. The stock had a trading volume of 613,600 shares, compared to its average volume of 1,067,737. Galena Biopharma has a fifty-two week low of $0.26 and a fifty-two week high of $3.60.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/12/14/brokerages-expect-galena-biopharma-inc-gale-will-post-earnings-of-0-15-per-share.html.

About Galena Biopharma

Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.

Get a free copy of the Zacks research report on Galena Biopharma (GALE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Galena Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.